期刊文献+

乳腺癌患者口服依维莫司的不良反应及防治措施 被引量:3

Adverse reactions of everolimus in cancer patients and preventive measures
下载PDF
导出
摘要 依维莫司(everolimus)是治疗晚期肾癌、晚期胰腺神经内分泌肿瘤、肾血管平滑肌脂肪瘤的靶向治疗药物,也是目前唯一已上市的口服哺乳动物雷帕霉素靶蛋白(mTOR)抑制剂。自2012年美国FDA(Food and Drag Admim's tration)批准依维莫司可用于绝经后雌激素受体阳性/Her-2阴性的晚期乳腺癌后,越来越多晚期乳腺癌患者在内分泌治疗的基础上口服依维莫司以期提高治疗效果。
出处 《现代临床护理》 2016年第12期55-58,共4页 Modern Clinical Nursing
基金 江苏省无锡市卫生局项目 项目编号为MD201210
关键词 依维莫司 乳腺癌 不良反应 everolimus breast cancer adverse reaction
  • 相关文献

参考文献11

二级参考文献101

  • 1中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2011版)[J].中国癌症杂志,2011,21(5):367-417. 被引量:266
  • 2FAIVRE S, KROEMER G, RAYMOND E. Current developmentof mTOR inhibitors as anticancer agents [ J ]. Nat Rev Drug Dis-cov, 2006,5(8) : 671 -688.
  • 3SANCHEZ-FRUCTUOSO AL Everolimus: an update on the mech-anism of action,pharmacokinetics and recent clinical trials [ J ].Expert Opin Drug Met, 2008,4(6) : 807 - 819.
  • 4JOHNSTON SR. Clinical efforts to combine endocrine agents withtargeted therapies against epidermal growth factor receptor/humanepidermal growth factor receptor 2 and mammalian target of rapa-mycin in breast cancer [ J ] . Clin Cancer Res,2006, 12(3):1061s- 1068s.
  • 5BURSTEIN HJ. Novel agents and future directions for refractorybreast cancer[ J]. Semin Oncol f 2011, 38(Suppl): sl7 - s24.
  • 6BOULAY A,RUDLOFF J, YE J, et al. Dual inhibition of mTORand estrogen receptor signaling in vitro induces cell death in mod-els of breast cancer [ J ]. Clin Cancer Res, 2005,11 ( 14 ):5319 -5328.
  • 7O’DONNELL A, FAIVRE S, BURRIS HA, et al. Phase I phar-macokinetic and pharmacodynamic study of the oral mammaliantarget of rapamycin inhibitor everolimus in patients with advancedsolid tumors[J]. J Clin Oncol, 2008, 26(10) : 1588 - 1595.
  • 8JACOBSEN W, SERKOVA N, HAUSEN B, et al. Comparisonof the in vitro metabolism of the macrolide immunosuppressantssirolimus and RAD [ J] . Transplant Proc,2001,33 ( 1 - 2 ):514 -515.
  • 9KOVARIK JM, SABIA HD,FIGUEIREDO J, et al. Influence ofhepatic impairment on everolimus pharmacokinetics : implicationsfor dose adjustment [ J ]. Clin Pharmacol Ther,2001,70 ( 5 ):425 -430.
  • 10TABEKNKHO J, ROJO F, CALVO E, et al. Dose-and sched-ule-dependenl inhibition of ihe mammalian target of tapamycinpathway with everolimus : a phase 1 tumor pharmacodynamic studyin patients with advanced solid tumors [ J ]. J Clin Oncol, 2008 ,26(10) : 1603 - 1610.

共引文献87

同被引文献17

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部